Spero Therapeutics, Inc. (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. The firm is developing first in class therapeutics for treatment of Gram-negative infections and went public in November 2017 - roughly coincident with their first SBIR Award. Spero Therapeutics is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
